Bridge Health was founded on continuous manufacturing science and expanded through engineering, scale-up, and industrial deployment. We are a specialist firm empowered by continuous manufacturing expertise that spans from primary research and filed patents through to commercial-scale delivery under federal oversight.
Continuous manufacturing expertise has historically been concentrated within academic institutions and large pharmaceutical R&D organizations. Bridge Health makes those capabilities accessible to emerging companies, manufacturers, and sovereign health initiatives — while providing the engineering and industrial execution required to turn scientific advances into commercial reality.
Most firms in this space are built on operational, regulatory, or engineering experience. Bridge Health is built on the science itself — and the full-stack capability to move from research through pilot to deployment. That means chemical, process, and instrument engineers working alongside R&D, process, and analytical chemists, QC specialists, and regulatory and procurement officers — everything needed to take a molecule from concept to validated commercial production.
Co-Founder & CEO
Dr. Kerry Gilmore conducted his foundational research at the Max Planck Institute of Colloids and Interfaces in Potsdam, Germany — one of the world’s leading centers for chemical and biological research.
There, he co-developed a continuous-flow photochemical synthesis process for artemisinin — the active pharmaceutical ingredient in the world's most effective malaria treatment. The process uses chlorophyll compounds from the Artemisia plant itself as the photosensitizer, eliminating the need for external chemical catalysts. It was novel, designed from day one for industrial scale, and patented through the Max Planck Society.
Over 60 peer-reviewed publications with more than 8,000 academic citations — placing Dr. Gilmore among the most cited flow chemists of his career stage globally.
Co-Founder & CFO
Bridge Health is built on two things: the manufacturing science to design processes that work, and the commercial and financial discipline to deliver them at scale. Sanjiv Malalasekera brings the second half of that equation.
With over 30 years of experience across accounting, consulting, and international banking — including senior positions at Arthur Andersen/Ernst & Young (Sydney and London), Credit Suisse (London), Morgan Stanley (Sydney), and ANZ Bank (Singapore) — Sanjiv brings the financial rigour and cross-border commercial judgment that complex manufacturing programs demand.
His career has spanned the disciplines that govern how large-scale projects get funded, structured, and delivered: capital markets, financial advisory, and management consulting at the highest level. That experience translates directly into how Bridge Health structures its engagements — with commercial accountability, governance, and program integrity built in from day one.
What he brings
Australia · United Kingdom · Singapore
Filing a patent is a legal milestone. Commercialising one under regulatory scrutiny — with government funders, production targets, and global health stakeholders all in the picture — is an operational and institutional challenge of a different scale entirely.
Our first client secured a contract under the US Department of Health and Human Services Program, part of a $32.4 million federal initiative to onshore production of critical medicines. The client required continuous manufacturing expertise and working knowledge of how to produce artemisinin to scale. Dr. Gilmore had the expertise and founded Bridge Health to implement it into an executable service.
The mandate was to design, build, and validate a complete continuous manufacturing system for artemisinin at 25% of global unmet demand (50 tons per year). The timeline: two years, January 2025 to December 2026.
That work is underway. By end of 2026, Bridge Health will have delivered and validated commercial-scale equipment that didn't previously exist — purpose-built for continuous flow production of essential medicines.
The partnership has since expanded to include domestic production of shikimic acid — the key starting material for Tamiflu — demonstrating that the platform extends across essential medicines, not a single molecule.
Every service is backed by hands-on experience, from the chemistry bench to commercial production.
Continuous manufacturing transitions are expensive, complex, and high-stakes. Getting them wrong costs years and tens of millions. At Bridge Health, the answer to that question is yes.
Talk to us about your programWe work with a focused number of clients at any one time. If continuous manufacturing is on your agenda — at any stage — we'd like to hear from you.
